MedTrace Logo

Colchicine in Coronary Artery Bypass Graft (CABG)

NCT02122484 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-11-11

No results posted yet for this study

Summary

There is evidence that inflammatory processes may play a key role during surgical myocardial reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent, may lead to reduction in periprocedural infarct size, when administered during elective coronary artery bypass graft surgery.

Conditions

  • Elective Coronary Artery Bypass Graft Surgery

Interventions

DRUG

Colchicine

colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation

Sponsors & Collaborators

  • Evangelismos Hospital

    collaborator OTHER

  • G.Gennimatas General Hospital

    lead OTHER

Principal Investigators

  • Spyridon Deftereos, MD · Athens General Hospital "G. Gennimatas"

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-06-30
Completion
2014-11-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02122484 on ClinicalTrials.gov